Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Endoxana, IMA901, Leukine
Endoxana, Leukine, IMA910 · 2 trials · 2 indications
Safety assessment with special emphasis on the inclusion of the first 6 patients enrolled according to a pre-specified enrolment plan
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant |
| 2 | OTHER | No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant |
| Name | Type | Description |
|---|---|---|
| Endoxana, IMA901, Leukine | DRUG | a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901 |
| IMA901 and Leukine | DRUG | Intradermal injection of GM-CSF followed by intradermal injection of IMA901 |
| Endoxana, Leukine, IMA910 | DRUG | a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 |
| Endoxana, Leukine, IMA910, Aldara | DRUG | a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod) |
Inclusion Criteria: * Aged at least 18 years * HLA type: HLA-A\*02-positive * Histologically documented advanced clear-cell RCC * Patients who have received first-line tyrosine kinase inhibitor or cytokine systemic therapy for advanced disease systematic therapy for advanced disease and must be can...
IMA910 is an investigational oncology therapy developed by Immatics N.V. (ticker IMTX) for advanced colorectal carcinoma. It was studied in a Phase 1 trial as a combination regimen with GM-CSF and low-dose cyclophosphamide pre-treatment in patients who had completed a successful 12-week first-line oxaliplatin-based chemotherapy regimen.
IMA910 was evaluated in advanced colorectal carcinoma as a treatment following a successful 12-week first-line oxaliplatin-based chemotherapy regimen. The Phase 1 trial combined IMA910 with GM-CSF and low-dose cyclophosphamide pre-treatment. The study enrolled 92 patients across Belgium, Bulgaria, Germany, Hungary, Latvia, Poland, Romania, Serbia, and the United Kingdom.
IMA910 is being developed by Immatics N.V., which trades under the ticker IMTX. The company is the sponsor of the clinical program investigating IMA910 in advanced colorectal carcinoma and IMA901 in renal cell carcinoma.
IMA910 is in Phase 1 clinical development. The Phase 1 trial, NCT00785122, evaluated IMA910 plus GM-CSF with low-dose cyclophosphamide pre-treatment in advanced colorectal carcinoma patients and has been completed. No active trials are currently listed for IMA910.
IMA910 has been studied in one completed Phase 1 trial, NCT00785122, titled IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy. The trial enrolled 92 patients across nine European countries and is no longer active.
No, IMA910 and IMA901 are distinct investigational agents. IMA910 was studied in advanced colorectal carcinoma in a Phase 1 trial, while IMA901 was studied in advanced renal cell carcinoma in a Phase 2 trial, NCT00523159, which enrolled 68 patients. Both were developed by Immatics N.V.